An expensive eye injection that’s approved to treat macular degeneration — the most common cause of age-related blindness — works no better than a much cheaper drug at preventing vision loss. That’s the finding of a long-awaited study published online yesterday by the New England Journal of Medicine.
The study, involving more than 1,200 patients with the “wet’’ form of macular degeneration, found no difference between those who were randomly treated for one year with the more expensive drug Lucentis — which costs about $2,000 a dose — and the cheaper drug Avastin, which costs $50.
Monday, May 02, 2011
$50 eye drug found equal to $2,000 dose - Boston.com
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment